Disclosure of elevated amyloid status is not associated with long‐term suicidality in a preclinical AD trial

• DOI: 10.1002/alz.14623
• Publication Date: 2025-03-12T01:10:50Z
• Authors: Joshua D. Grill; Rema Raman; Charlene Flournoy; Karin Ernstrom; Aimee Pierce; Amanda Smith; Paul Rosenberg; Jeffrey Burns; Jason Karlawish; Paul Aisen; Karen Chilcott Ho...; Michele Mancini; Reisa Sperling; David Sultzer
• Keywords: Amyloid (mycology)

Abstract INTRODUCTION The long‐term implications of disclosing Alzheimer's disease (AD) biomarker information to cognitively unimpaired individuals are unknown. METHODS We compared participants who disclosed their elevated amyloid imaging result in a preclinical AD trial those not and enrolled an observational cohort that underwent parallel assessments. Our primary outcome was score > 0 on the Columbia Suicidality Severity Rating Scale (CSSRS) at any visit; we also considered suicidal behaviors (CSSRS 5). RESULTS Among 1707 total (68% amyloid, mean [standard deviation] age 71.5 [4.7], 60% female, 90% non‐Hispanic White), followed for 218 (74.1) weeks, there were no suicides few indications thoughts ( n = 124 [7%]) or 13 [<1%]). In generalized estimating equation model controlling covariates, observed effect status CSSRS (odds ratio 1.6, 95% confidence interval 0.76, 3.37). DISCUSSION With structured approach, brain results can be returned safely. Highlights Anti‐Amyloid Treatment Asymptomatic study among first largest studies include disclosure population without cognitive impairment. Routine psychological assessment provided novel impact this sample. Learning through protocolized approach associated with matched learned they did have amyloid. Future research will needed ensure similar safety more real‐world settings.